According to the company, NimbleGen comparative genomic hybridization (CGH) 12x135K arrays allow simultaneous analysis of 12 independent sample pairs on a single microarray slide, each with 135,000 empirically tested long oligonucleotide probes.
This new array format will enable rapid and cost-effective analysis of DNA copy number variation associated with human genetic disease, genomic disorders, cancer, and other complex diseases for research purposes, the company said.
The launch of NimbleGen CGH 12x135K arrays is further supported with a new release of Roche NimbleGen’s NimbleScan v2.5 software that includes an experimental metrics report and enhanced analysis features for NimbleGen CGH arrays.
Gerd Maass, CEO of Roche NimbleGen, said: “The launch of NimbleGen CGH 2.1M and 12x135K arrays positions Roche NimbleGen as a leading provider of CGH microarrays and services offering both ultra-high resolution discovery and large-scale validation of copy number variants on a single platform.
“These tools will facilitate the identification of genetic variants associated with a variety of rare and common diseases including diabetes, cancer, psychiatric disorders, and autoimmune disease.”